Last updated: October 21, 2026
COSOPT is a mature fixed-dose ophthalmic combination of dorzolamide hydrochloride 2% and timolol maleate 0.5% used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The product was developed by Merck and is now associated with Bausch + Lomb’s ophthalmic portfolio. Its commercial position is defined by generic substitution, low-cost therapeutic alternatives, and declining branded pricing rather than patent exclusivity.
COSOPT remains clinically relevant because it combines a carbonic anhydrase inhibitor and a beta blocker in one bottle. Its financial trajectory is mature and defensive: prescription demand persists, but branded revenue is constrained by long-standing generic competition and the availability of separate dorzolamide and timolol products.
What is COSOPT and how does it work?
COSOPT is a topical ophthalmic solution containing:
| Product |
Active ingredients |
Strength |
FDA dosage form |
| COSOPT |
Dorzolamide hydrochloride and timolol maleate |
2% / 0.5% |
Multidose ophthalmic solution |
| COSOPT PF |
Dorzolamide hydrochloride and timolol maleate |
2% / 0.5% |
Preservative-free single-dose ophthalmic solution |
Dorzolamide reduces aqueous humor production through carbonic anhydrase inhibition. Timolol reduces aqueous humor production through beta-adrenergic blockade. The combination can reduce dosing frequency compared with using the two ingredients separately.
The principal indications are elevated intraocular pressure in open-angle glaucoma and ocular hypertension. COSOPT is generally used when monotherapy is inadequate or when a combination regimen is clinically appropriate. It is not a prostaglandin analogue and competes in a treatment pathway that includes latanoprost, bimatoprost, travoprost, brimonidine, brinzolamide, and fixed-dose combinations.
When did COSOPT receive FDA approval?
The FDA approved COSOPT in 1998 under New Drug Application 020408. Merck was the original sponsor. COSOPT PF was subsequently approved as a preservative-free version under a separate FDA application.
Key regulatory milestones include:
| Milestone |
Approximate date |
Commercial significance |
| COSOPT FDA approval |
1998 |
Established the dorzolamide-timolol fixed-dose product |
| Generic dorzolamide-timolol approvals |
2000s onward |
Created direct substitution pressure |
| COSOPT PF approval |
2010s |
Added a preservative-free formulation for patients sensitive to benzalkonium chloride |
| Branded ophthalmology portfolio transfers |
2010s |
Moved commercial responsibility away from Merck |
| Current market |
Mature |
Generic and therapeutic competition dominate |
The product is regulated as a prescription ophthalmic drug, not as a biologic. Biosimilar pathways therefore do not apply. Competitive products are approved through abbreviated new drug applications, or ANDAs, when they demonstrate pharmaceutical equivalence and bioequivalence.
What patents protected COSOPT?
COSOPT’s original patent position centered on the fixed combination of dorzolamide and timolol, ophthalmic formulations, and related methods of reducing intraocular pressure. The core United States patent protection has expired.
Public patent records associated with dorzolamide, timolol, and the COSOPT combination include historical Merck patents covering:
- Dorzolamide compounds and carbonic anhydrase inhibition.
- Ophthalmic formulations of dorzolamide.
- Fixed-dose dorzolamide-timolol combinations.
- Methods of treating elevated intraocular pressure.
The precise patent portfolio varied by jurisdiction and by product presentation. Patents covering the original COSOPT product no longer provide meaningful United States exclusivity. Any remaining patent issues are more likely to concern a particular formulation, manufacturing process, device, or preservative-free presentation than the basic combination itself.
Does COSOPT have active Orange Book protection?
COSOPT is no longer commercially protected by an effective period of United States new-drug exclusivity. Its original regulatory exclusivity and core patent term expired many years ago. FDA Orange Book listings for mature products can include historical patents, delisting events, or patents tied to particular presentations, but the commercial product has faced generic competition for an extended period.[1]
The relevant business conclusion is that COSOPT has no practical U.S. monopoly based on the original composition. Generic manufacturers can market equivalent dorzolamide hydrochloride/timolol maleate ophthalmic solutions subject to FDA approval.
When did COSOPT lose exclusivity?
COSOPT lost effective exclusivity during the 2000s as generic dorzolamide-timolol products entered the U.S. market. The exact commercial erosion date varied by manufacturer, dosage form, and market channel.
| Exclusivity factor |
Current position |
| FDA new-drug exclusivity |
Expired |
| Core composition patents |
Expired |
| Fixed-combination market exclusivity |
Expired |
| Paragraph IV exposure |
Historically relevant, but no longer a central barrier |
| Generic substitution |
Established |
| Preservative-free differentiation |
Limited commercial protection without durable exclusivity |
The absence of current core exclusivity means that pricing is determined primarily by generic supply, wholesaler contracts, formulary placement, pharmacy substitution, and manufacturer reliability.
Which companies compete with COSOPT?
Competition comes from both direct generic equivalents and alternative glaucoma therapies.
Direct generic competitors
Manufacturers of dorzolamide hydrochloride and timolol maleate ophthalmic solution have included multiple generic drug companies over time. Market participation can change because of shortages, manufacturing withdrawals, or product discontinuations. The relevant competitive set includes companies that have received FDA approval for the same active ingredients, concentrations, route, and dosage form.
Direct substitutes generally compete on:
- Wholesale acquisition cost.
- Generic reimbursement.
- Contract availability.
- Bottle design and ease of use.
- Supply reliability.
- Preservative profile.
- Pharmacy substitution status.
Therapeutic competitors
| Competitive class |
Examples |
Competitive effect |
| Prostaglandin analogues |
Latanoprost, bimatoprost, travoprost |
Often used as first-line therapy |
| Alpha agonists |
Brimonidine |
Alternative or add-on therapy |
| Carbonic anhydrase inhibitors |
Brinzolamide, dorzolamide |
Compete with the dorzolamide component |
| Beta blockers |
Timolol |
Compete with the timolol component |
| Fixed combinations |
Brimonidine-timolol, brinzolamide-brimonidine |
Reduce the need for separate or COSOPT therapy |
| Surgical and device-based treatments |
Laser trabeculoplasty, minimally invasive glaucoma surgery |
Reduce long-term dependence on topical drops in selected patients |
Latanoprost and other prostaglandin analogues represent the largest strategic threat to older beta blocker-containing combinations because they are widely used as initial pharmacologic therapy and generally require once-daily administration.
What formulations are protected by COSOPT?
COSOPT is available in a conventional multidose solution. COSOPT PF is a preservative-free single-dose formulation intended to reduce exposure to preservatives such as benzalkonium chloride.
The preservative-free product targets patients with:
- Ocular surface disease.
- Chronic exposure to multiple preserved eye drops.
- Contact-lens-related intolerance.
- Inflammation or irritation attributed to preservatives.
- A need for long-term glaucoma therapy with improved tolerability.
COSOPT PF has greater formulation differentiation than the original product, but formulation differentiation does not automatically create durable market exclusivity. A competitor can challenge the product through an ANDA or develop a different preservative-free fixed combination, subject to FDA requirements.
The formulation opportunity is commercially meaningful because glaucoma patients often use multiple chronic ophthalmic medications. Tolerability, drop burden, packaging, and adherence can support premium pricing even when the active ingredients are generic.
How strong is the COSOPT patent estate?
The current patent estate is weak as a barrier to generic entry. The basic product has been available long enough for the principal composition and use patents to expire. Product value now depends on brand recognition, physician familiarity, supply continuity, and formulation positioning.
| Patent-estate factor |
Assessment |
| Core active ingredients |
Weak barrier; longstanding generic availability |
| Fixed-dose combination |
Weak barrier; mature generic category |
| Method-of-use protection |
Expired or commercially ineffective for the core indication |
| Preservative-free formulation |
Potentially differentiated, but not a broad monopoly |
| Manufacturing know-how |
Relevant to quality and supply, but not a substitute for market exclusivity |
| Device or packaging protection |
Limited impact unless tied to a differentiated delivery system |
Manufacturing remains operationally important. Ophthalmic solutions require sterile production, validated filling, container-closure integrity, particulate control, and reliable preservative or preservative-free handling. These requirements can limit the number of dependable suppliers, but they do not prevent generic competition when approved products are available.
Are there Paragraph IV challenges involving COSOPT?
Paragraph IV litigation was principally relevant during the period when generic manufacturers first challenged listed patents. Because COSOPT’s core patents have expired, current commercial risk is not centered on a new wave of Paragraph IV litigation against the original product.
For mature ophthalmic products, generic entry can occur through:
- A standard ANDA after relevant patents expire.
- A Paragraph IV certification against remaining listed patents.
- A product-specific challenge to formulation or use patents.
- A separate approval route for a different preservative-free presentation.
The commercial consequence is that future litigation risk is more likely to arise around a new formulation, delivery system, or method-of-use claim than around the original COSOPT combination.
What is the FDA regulatory status of COSOPT?
COSOPT is an FDA-approved prescription ophthalmic drug. Its active ingredients have established safety and efficacy histories, and generic versions are eligible for ANDA approval when they meet FDA equivalence requirements.
The main regulatory issues for the category are:
- Sterility assurance.
- Bioequivalence and pharmaceutical equivalence.
- Concentration and pH control.
- Container and drop-delivery performance.
- Preservative content.
- Stability after opening.
- Labeling for contraindications and systemic beta blocker risks.
Timolol-containing products carry class-related risks, including bronchospasm, bradycardia, hypotension, and cardiac conduction effects. Dorzolamide can cause local ocular irritation and other carbonic anhydrase inhibitor-related reactions. These safety characteristics affect prescribing and payer management but do not provide branded patent protection.
What is COSOPT’s financial trajectory?
Bausch + Lomb and predecessor owners have not consistently disclosed COSOPT revenue as a standalone line item. Public company reporting generally groups mature ophthalmic products into broader prescription pharmaceutical or surgical and pharmaceutical segments. As a result, a precise annual COSOPT revenue series is not publicly available from company filings.
The financial trajectory can be summarized as follows:
| Period |
Financial profile |
| Launch and early growth |
Premium branded combination supported by patent and regulatory protection |
| Generic-entry period |
Rapid price and share erosion |
| Mature branded period |
Lower-volume, lower-price product with persistent clinical demand |
| Current period |
Revenue supported by brand prescriptions, formulation preference, and supply reliability |
| Long-term outlook |
Stable-to-declining branded sales, with limited pricing power |
Revenue pressure comes from four sources:
- Generic substitution.
- Low-cost separate dorzolamide and timolol therapy.
- Prostaglandin analogues used earlier in treatment.
- Payer preference for lower-cost products.
Revenue support comes from chronic disease prevalence, physician familiarity, fixed-dose convenience, and continued use among patients who respond to the combination. Preservative-free COSOPT PF may command better net pricing than conventional generic products, although its addressable market is smaller.
What generic launch scenarios exist for COSOPT?
The most likely market scenarios are:
Base case: continued generic dominance
Generic dorzolamide-timolol remains the primary volume product. Branded COSOPT retains a smaller segment of prescriptions where physicians, patients, or payers value continuity and product familiarity.
Downside case: further branded erosion
Additional generic suppliers or lower reimbursement reduce branded utilization and net price. Pharmacy substitution increases, and the branded product becomes concentrated in less price-sensitive channels.
Upside case: preservative-free or supply-driven recovery
A generic shortage, manufacturing disruption, or increased concern about ocular-surface tolerability could support COSOPT PF or the branded product. This would likely produce temporary share or price improvement rather than restore historical exclusivity economics.
What licensing deals and ownership changes affect COSOPT?
COSOPT originated with Merck. Merck later transferred or divested portions of its ophthalmology portfolio, and products including COSOPT became associated with Bausch + Lomb and its parent-company structure.
These portfolio transactions matter because they changed:
- Commercial ownership.
- Distribution arrangements.
- Product-level reporting.
- Manufacturing responsibilities.
- Portfolio strategy for mature ophthalmic medicines.
Public disclosures have generally not provided a standalone COSOPT valuation or transaction price. The product should therefore be analyzed as part of broader ophthalmology portfolio transactions rather than as an independently reported asset.
What patent litigation affects COSOPT?
No active, high-value U.S. patent dispute appears to define the current COSOPT commercial market. The principal litigation risk occurred during the historical generic-entry period, when manufacturers could challenge listed patents or seek approval after patent expiration.
Current disputes, if any, would more likely involve:
- Specific generic labeling.
- Manufacturing quality.
- Supply interruptions.
- Product liability.
- Reformulated or preservative-free versions.
- Trademark or unfair-competition claims.
Those issues are narrower than a core composition patent case and are unlikely to recreate the original product’s exclusivity.
How does COSOPT compare with competing glaucoma drugs?
| Product or class |
Dosing advantage |
Patent position |
Commercial position |
| COSOPT |
Fixed combination, typically twice daily |
Expired core protection |
Mature branded and generic market |
| Generic dorzolamide-timolol |
Same active combination |
No meaningful core exclusivity |
Lowest-cost direct substitute |
| Latanoprost |
Once daily |
Core product protection expired in major markets |
Strong first-line competition |
| Brimonidine-timolol |
Fixed combination |
Mature market |
Competes for combination therapy |
| Brinzolamide-brimonidine |
Fixed combination |
More recent formulation history |
Differentiated combination option |
| Timolol alone |
Simple beta blocker therapy |
Generic |
Low-cost alternative |
| Dorzolamide alone |
Carbonic anhydrase inhibitor |
Generic |
Used when beta blockers are unsuitable |
COSOPT’s strongest competitive attribute is convenience within a familiar, established regimen. Its weakest attributes are twice-daily dosing, beta blocker-related contraindications, generic price pressure, and competition from once-daily prostaglandin analogues.
Key Takeaways
- COSOPT is a mature fixed-dose ophthalmic combination of dorzolamide hydrochloride and timolol maleate.
- FDA approval dates to 1998, and core U.S. patent and regulatory exclusivity have expired.
- Generic dorzolamide-timolol products are the primary direct competitors.
- No biosimilar pathway applies because COSOPT is a small-molecule ophthalmic drug.
- COSOPT PF provides preservative-free differentiation but does not restore broad composition-level exclusivity.
- Standalone COSOPT revenue is not separately disclosed in a consistent public reporting series.
- Branded revenue is likely stable to declining, with value concentrated in chronic demand, physician familiarity, formulation preference, and supply reliability.
- Future market risk is commercial rather than primarily patent-driven.
- The main competitive threats are generic substitution, latanoprost and other prostaglandin analogues, and newer fixed combinations.
- Manufacturing quality and sterile ophthalmic supply can affect market share, but they are not substitutes for patent protection.
Frequently Asked Questions
Is COSOPT still under patent?
The core COSOPT combination is no longer protected by an effective U.S. composition patent monopoly. Specific formulation or presentation patents must be evaluated separately.
Is generic COSOPT available?
Yes. Generic dorzolamide hydrochloride and timolol maleate ophthalmic solutions are available in the U.S. market, subject to manufacturer supply and pharmacy stocking.
Is COSOPT PF generic?
Generic availability for the preservative-free presentation is more limited than for conventional multidose dorzolamide-timolol solution. The formulation and packaging requirements create greater manufacturing complexity.
Does COSOPT have exclusivity for glaucoma treatment?
No. COSOPT does not have broad current exclusivity for the treatment of glaucoma or ocular hypertension. Competing fixed combinations and separate generic ingredients are available.
Who owns the COSOPT brand?
COSOPT originated with Merck and later became associated with Bausch + Lomb’s ophthalmology portfolio. Current commercial ownership and distribution should be confirmed against the latest FDA and company product records.
References
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Electronic Orange Book data files. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
Bausch + Lomb Corporation. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. https://ir.bausch.com/
-
U.S. Food and Drug Administration. (2023). Cosopt prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
U.S. Food and Drug Administration. (2023). Cosopt PF prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
